In only six weeks, Cebiotex’s crowdfunding round on Capital Cell has successfully closed, achieving the set objective of 600,000€ and reaching 125% of investment, with 750,000€ The total amount of investors has been 174.
In November 2020, Cebiotex announced the launch of a new funding round of 1.6M€, including its 4th crowdfunding. The objective is to raise funds to continue the clinical trials with adult patients and hence reach the goal of initiating clinical studies with paediatric patients alongside Hospital Sant Joan de Déu. Moreover, the start-up aims to reach the first real Exit window to either license its drug CEB-01, or its technology, to the pharmaceuticals.
According to the initial comments of Joan Bertran, CEO and cofounder of Cebiotex,
“These two milestones suppose the completion of a successful Social Impact Investment. With it, we prove that it is possible to invest in projects for children while obtaining important returns.”
In August 2020, the drug CEB-01 was successfully implanted for the first time in a patient at the Hospital de la Santa Creu i Sant Pau in Barcelona, with Dr. Pousa as the director of the clinical study, showing extremely promising results.
